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Introduction {#sec001}
============

Numerous viruses relevant to human and animal health utilize a lympho-hematogenous route of dissemination whereby they penetrate their hosts though disruptions of epithelial surfaces such as the skin, spread to the draining lymph node (dLN) *via* afferent lymphatics, and become systemic by disseminating to the blood through efferent lymphatics \[[@ppat.1008239.ref001]\]. However, our understanding of how the host innate immune system mechanistically induces protective resistance to the virus during lympho-hematogenous dissemination is incomplete. Ectromelia virus (ECTV), a member of the Orthopoxvirus genus of large, closely-related DNA viruses and the causative agent of mousepox (the mouse homolog of human smallpox) is the archetype used to study lympho-hematogenous dissemination \[[@ppat.1008239.ref001]--[@ppat.1008239.ref004]\].

Type I interferons (IFN-I), which in the mouse, include one IFN-β and 14 IFN-α, are produced rapidly following viral infection. IFNs induce a Janus kinase signal transducer and activator of transcription-mediated (JAK-STAT) pathway that leads to the transcriptional regulation of several hundred interferon stimulated genes (ISGs) that are collectively involved in the coordinated effort to resist and control viral spread and pathogenicity \[[@ppat.1008239.ref005]--[@ppat.1008239.ref007]\]. Two lines of evidence demonstrate the importance of IFN-I in resistance to mousepox. First, C57BL/6(B6) mice are resistant to mousepox, but B6 mice deficient in the IFN-I receptor (IFNAR) subunit IFNAR1 have very high levels of viral replication, dissemination and succumb to mousepox \[[@ppat.1008239.ref008]--[@ppat.1008239.ref010]\]. Second, ECTV encodes EVM166, a IFN-I decoy receptor, that is critical for ECTV virulence in susceptible mice but is still pathogenic in IFNAR1 deficient mice \[[@ppat.1008239.ref009]\]. Notably, EVM166 inactivates mouse IFNα but not IFNβ suggesting that only IFNα is critical for resistance to mousepox \[[@ppat.1008239.ref009]\].

The production of IFN-I, and also of many inflammatory cytokines and chemokines, requires sensing of infection through pathogen recognition receptors (PRR) \[[@ppat.1008239.ref011]--[@ppat.1008239.ref014]\]. PRRs are a class of germline-encoded receptors that recognize pathogen-associated molecular patterns (PAMP), typically conserved molecular motifs with repetitive structures such as lipopolysaccharide, RNA and DNA \[[@ppat.1008239.ref011]\]. PAMPs in the cell microenvironment are surveyed by membrane bound PRRs that are either at the cell surface or on endocytic compartments, such as Toll-like receptor 9 (TLR9) which recognizes viral CpG DNA. The cytosolic TIR domain of TLR9 and most other TLRs directly interact with the adapter Myeloid differentiation primary response 88 (MyD88) which becomes phosphorylated upon PAMP sensing. This activates a cascade of signaling molecules that culminates in the activation of transcription factors such as IRF3, IRF7, and NF-κB that induce the transcription of IFN-I and/or proinflammatory cytokines and chemokines. PRRs in in the cytoplasm such as RIG-I like helicases (RLH) recognize viral RNA, while Interferon-activated gene 204 (Ifi204, IFI16 in humans), and cyclic-GMP-AMP (cGAMP) synthase (cGAS) recognize viral DNA \[[@ppat.1008239.ref012]--[@ppat.1008239.ref015]\]. cGAS synthesizes the messenger cGAMP which bind Stimulator of Interferon Genes (STING) to induce IRF3, IRF7, NF-κB or other transcription factors to stimulate the transcription of IFN-I and chemokines and cytokines \[[@ppat.1008239.ref012]\]. Ifi204/IFI16 also works through STING but the specific mechanism is not understood.

We have previously demonstrated cooperation between sensing pathways in response to ECTV, in which MHC-II^hi^ dendritic cells (DCs) from the skin migrate to the dLN and produce the chemokines CCL2 and CCL7 in a TLR9-MyD88-IRF7 dependent manner to recruit inflammatory monocytes (iMO) to the dLN \[[@ppat.1008239.ref016],[@ppat.1008239.ref017]\]. We also showed that in the dLN iMOs become infected and use STING-IRF7 and STING-NF-κB to respectively induce IFNα and IFNβ \[[@ppat.1008239.ref016]\]. We also showed that during lympho-hematogenous ECTV spread, iMOs and not plasmacytoid DCs (pDCs) are the main producers of IFN-I. Yet, the PRR(s) responsible for IFN-I induction upstream of STING remained unidentified. Very recently, Cheng et al. showed that cGAS upstream of STING is important for IFNβ production and resistance to mousepox with high ECTV doses \[[@ppat.1008239.ref018]\] but its role in the induction of the more critical IFNα or ISGs and the *in vivo* cellular requirements were not investigated. Here we confirm that cGAS is necessary for resistance to mousepox, in our case to relatively low viral doses, and that it is important for efficient IFNβ expression. We also demonstrate that cGAS is important for optimal expression of more relevant IFNα and also ISGs. Furthermore, we demonstrate that resistance to mousepox necessitates cGAS in bone marrow-derived (BMD) cells but not in parenchymal cells. We further show that cGAMP administration at the site of infection prevents lethal mousepox in cGAS deficient mice by curbing virus spread through the induction of IFN-I and ISGs. Mechanistically, cGAMP rescue requires the transcription factor IRF7 and the IFN-I receptor IFNAR1. Together, these findings demonstrate that early sensing of virus by BMD cells *via* cGAS is critical to control a highly pathogenic DNA viral infection, and highlights the importance that curbing virus spread from the initial site of infection.

Methods {#sec002}
=======

Mice {#sec003}
----

All mice used in experiments were 6--12 weeks old. C57BL/6 (B6) mice were purchased from Charles River. Cgas^-/-^ mice were a gift from Zhijian Chen (UT Southwestern Medical Center, Dallas TX). *Tmem173*^*gt*^ (C57BL/6J-*Tmem173*^*gt*^/J) were originally purchased from Jackson Laboratories (Bar Harbor, ME). *Irf7*^*-/-*^ (B6.129P2-Irf7^tm1Ttg^/TtgRbrc) were from Riken Bioresource Center (Tsukuba, Japan). *Ifnar1*^*-/-*^ mice backcrossed to B6 were a gift from Dr. Thomas Moran (Mount Sinai School of Medicine, New York, NY). *Ifi204*^*-/-*^ mice were generated from frozen germplasm from the Knockout Mouse Project (KOMP) Repository (UC Davis, Davis CA). Colonies were bred at Thomas Jefferson University under specific pathogen free conditions.

Viruses and infection {#sec004}
---------------------

Virus stocks, including ECTV-Moscow strain (WT) (ATCC VR-1374), ECTV-EGFP \[[@ppat.1008239.ref019]\] and ECTV-dsRED \[[@ppat.1008239.ref020]\] were propagated in tissue culture as previously described \[[@ppat.1008239.ref009]\]. Mice were infected with 3,000 plaque forming units (PFUs) ECTV-WT, ECTV-EGFP or ECTV-dsRED as indicated. For the determination of survival, mice were monitored daily and to avoid unnecessary suffering, mice were euthanized and counted as dead when imminent death was certain as determined by lack of activity and unresponsiveness to touch. Euthanasia was according to the 2013 edition of the AVMA Guideline for the Euthanasia of Animals. For virus titers, the entire spleen or portions of the liver were homogenized in RPMI using a Tissue Lyser (QIAGEN). Virus titers were determined on BSC-1 cells as described before \[[@ppat.1008239.ref009]\].

Production of bone marrow chimeric mice {#sec005}
---------------------------------------

Bone marrow chimeras were prepared as previously described \[[@ppat.1008239.ref021]\]. Briefly, 6- to 8-week-old mice were irradiated with 900 rads using a GammaCell 40 apparatus (Nordion Inc.). Irradiated mice were reconstituted intravenously with an inoculation of 2-5x10^6^ bone marrow cells from different donors. Chimeras were administered with acidified water and rested for 8 weeks after reconstitution.

cGAMP administration {#sec006}
--------------------

To investigate the effect of exogenous cGAMP during infection, 10 ug of 2'3' cGAMP (Invivogen) or control PBS was injected into the footpad 4 hours prior to infected with ECTV.

Flow cytometry {#sec007}
--------------

Flow cytometry was performed as previously described \[[@ppat.1008239.ref009]\]. The following Abs were used: BV785-CD3ε (Clone 145-2C11), BV711-CD8α (Clone 53--6.7), APC/Cy7-CD11b (Clone M1/70), BV-421-Gr-1 (Clone RB6-8C5), PE/Cy7-CD11c (Clone N418), FITC-CD45 (Clone I3/2.3), PerCP/Cy5.5-IA^b^ (Clone AF6-120.1), BV605-NK1.1 (PK136) were from Biolegend. BUV395-CD4 (Clone GK1.5) and BUV395-CD19 (Clone 1D3) were from BD Biosciences. To obtain single-cell suspensions, LNs were first incubated in Liberase TM (1.67 Wünsch units/mL) (Sigma) in PBS with 25 mM HEPES for 30 min at 37°C before adding PBS with 25 mM HEPES + 10% FBS to halt the digestion process, followed by mechanical disruption of the tissue through a 70-μm filter. Cells were washed once with FACS buffer (PBS with 1% BSA + 0.1% sodium azide) before surface staining. For analysis, samples were acquired using either a BD LSR II flow cytometer or a BD Fortessa flow cytometer (BD Biosciences), and data were analyzed with FlowJo software (TreeStar). For cell sorting, samples were acquired with a BD FACS Aria III sorter (BD Bioscience).

RNA preparation and RT-qPCR {#sec008}
---------------------------

Total RNA from LNs or sorted cells (10^4^−10^5^ cells) was obtained with the RNeasy Mini Kit (QIAGEN) as previously described \[[@ppat.1008239.ref010],[@ppat.1008239.ref016]\]. First-strand cDNA was synthesized with High Capacity cDNA Reverse Transcription Kit (Life Technologies). qPCR was performed as before \[[@ppat.1008239.ref010],[@ppat.1008239.ref016]\] using primers as follows: *Gapdh*: tgtccgtcgtggatctgac and cctgcttcaccaccttcttg, *Evm003*: tctgtcctttaacagcatagatgtaga and tgttaactcggaagttgatatggta, *Evm036*: tgccagttagcactgcgtat and aggtgttctggagaatcaaaga, *Ifng*: gcaaaaggatggtgacatga and ttcaagacttcaaagagtctgaggta, *Ccl2*: catccacgtgttggctca and gatcatcttgctggtgaatgagt, *Ccl7*: ttgacatagcagcatgtggat and ttctgtgcctgctgctcata, *Cxcl9*: cttttcctcttgggcatcat and gcatcgtgcattccttatca, *Il6*: tctaattcatatcttcaaccaagagg and tggtccttagccactccttc, *Tnf*: tcttctcattcctgcttgtgg and ggtctgggccatagaactga, *Mx1*: gatccgacttcacttccagatgg and catctcagtgtagtcaaccc, *Il12*: gactccaggggacaggcta and ccaggagatggttagcttctg, *Ifit3*: tgaactgctcagcccaca and tcccggttgacctcactc, *Isg15*: agtcgacccagtctctgactct and ccccagcatcttcaccttta, *Irf7*: tgtagtgtggtgacccttgc and cttcagcactttcttccgaga, *Ifnb1*: catttccgaatgttcgtcct and cacagccctctccatcaacta, *Ifna4*: gtcttttgatgtgaagaggttcaa and tcaagccatccttgtgctaa, *Ifna-non4*: aagctgtgtgatgcaacaggt and ggaacacagtgatcctgtgg.

Statistics {#sec009}
----------

Data were analyzed with Prism 6 software (GraphPad Software). For survival we used the Log-rank (Mantel-Cox). For other experiments ANOVA with Tukey correction for multiple comparisons or Student's t test were used as applicable. In all figures, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.001.

Ethics statement {#sec010}
----------------

All the procedures involving mice were carried out in strict accordance with the recommendations in the Eight Edition of the Guide for the Care and Use of Laboratory Animals of the National Research Council of the National Academies. All experiments were approved by Thomas Jefferson University's Institutional Animal Care and Use Committee under protocol number 01727 "Immune Control of Viral Infections".

Results {#sec011}
=======

cGAS, but not IFI204, is not required for resistance to ECTV infection {#sec012}
----------------------------------------------------------------------

Our previous work established the important role of STING, IRF7 and NF-κB in IFN-I induction during ECTV lympho-hematogenous dissemination \[[@ppat.1008239.ref016]\]. We had also explored a possible role for the DNA-dependent activator of IFN-regulator factors (DAI/Zbp1) as the PRR upstream of STING, but we found it was not required for resistance to ECTV or IFN-I induction \[[@ppat.1008239.ref016]\]. Thus, we set to identify the PRR upstream of STING. *Ifi204* is one of the few genes that mapped as a possible candidate to the still unidentified Resistance to Mousepox 4 (Rmp-4) gene \[[@ppat.1008239.ref022]\]. Notably, murine IFI204 and its human ortholog IFI16 are members of the PRR AIM2-like receptor family and have been shown to signal through STING \[[@ppat.1008239.ref023]--[@ppat.1008239.ref026]\]. This made *Ifi204* an intriguing candidate as an ECTV PRR. However, all *Ifi204*^*-/-*^ mice survived ECTV infection ([Fig 1A](#ppat.1008239.g001){ref-type="fig"}) and did not exhibit significant differences with WT B6 mice in viral replication in the dLN at 2.5 dpi, measured by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) as mRNA for the ECTV gene *Evm036* ([Fig 1B](#ppat.1008239.g001){ref-type="fig"}). Also, while *Ifi204*^*-/-*^ mice had a slight but significantly higher virus titers in the spleen at 7 dpi, there were no significant differences in viral burden in the liver compared to B6 controls ([Fig 1C and 1D](#ppat.1008239.g001){ref-type="fig"}). Furthermore, *Ifi204*^*-/-*^ mice had similar levels of mRNA for *Ifna-non4* (detected by RT-qPCR with a single primer pair as mRNA for all IFN-α except α4 \[[@ppat.1008239.ref027]\] and *Ifnb1* (encoding the single IFN-β) expression in the dLN compared to B6 mice ([Fig 1E and 1G](#ppat.1008239.g001){ref-type="fig"}). Thus, IFI204 is not a significant cytosolic PRR for IFN-I expression in response to ECTV infection or for ECTV control.

![cGAS, but not IFI204, is required for optimal resistance to ECTV infection.\
**(A)** Survival of the indicated mice. **(B)** Expression of *Evm036* in the dLN at 2 dpi of the indicated mice as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of two similar experiments. **(C-D)** Virus loads in the spleen (C) and liver (D) of the indicated mice at 7 dpi as determined by plaque assay. Data are displayed as the mean ± SEM of 4--5 mice per group. **(E-G)** Expression of IFN-I in the dLN at 2.5 dpi of the indicated mice as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three similar experiments. **(H)** Survival of the indicated mice. **(I-J)** Expression of *Evm036* in the skin (1 or 2 dpi) (I) and dLN (2 dpi) (J) of the indicated mice as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three similar experiments. **(K-L)** Virus loads in the spleen (K) and liver (L) of the indicated mice at 3, 5 or 7 dpi as determined by plaque assay. Data are displayed as the mean ± SEM of 5--6 mice per group. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](ppat.1008239.g001){#ppat.1008239.g001}

We investigated a possible role for cGAS, because it had been shown important for the control of the DNA virus herpes simplex-1 \[[@ppat.1008239.ref028]\]. We found that most B6 mice deficient in cGAS (*Cgas*^*-/-*^) succumbed to mousepox ([Fig 1H](#ppat.1008239.g001){ref-type="fig"}). Consistently, viral loads, measured by *Evm036* mRNA transcripts in the skin of the footpad at 1 and 2 dpi ([Fig 1I](#ppat.1008239.g001){ref-type="fig"}) and in the dLN at 2 dpi ([Fig 1J](#ppat.1008239.g001){ref-type="fig"}), were significantly higher in *Cgas*^*-/-*^ mice compared to B6 controls. Furthermore, the unrestricted viral replication permitted swift dissemination to peripheral organs, as *Cgas*^*-/-*^ mice had significantly higher viral titers in the spleen at 3, 5 and 7 dpi ([Fig 1K](#ppat.1008239.g001){ref-type="fig"}) and liver at 5 and 7 dpi ([Fig 1L](#ppat.1008239.g001){ref-type="fig"}). Thus, cGAS is necessary for ECTV control and resistance to lethal mousepox.

*Cgas*^*-/-*^ mice have a defective IFN-I and ISG response in the dLN after infection {#sec013}
-------------------------------------------------------------------------------------

To determine whether cGAS deficiency affects IFN, chemokines, cytokines and ISG gene transcription in the early innate immune response to ECTV during lympho-hematogenous spread, we isolated mRNA from the dLN of infected B6 and *Cgas*^*-/-*^ mice at 2.5 dpi and performed RT-qPCR to measure relative fold-change in gene expression over each group's contralateral ndLN. We found that cGAS deficiency resulted in significantly decreased, but not absent, transcription of the IFN-I genes *Ifna4* ([Fig 2A](#ppat.1008239.g002){ref-type="fig"}), *Ifna-non4* ([Fig 2B](#ppat.1008239.g002){ref-type="fig"}) and *Ifnb1* ([Fig 2C](#ppat.1008239.g002){ref-type="fig"}), which at this time point are mostly produced by infected iMOs \[[@ppat.1008239.ref016]\]. However, cGAS deficiency did not affect IFN-γ gene expression ([Fig 2D](#ppat.1008239.g002){ref-type="fig"}), which is produced mostly by NK cells \[[@ppat.1008239.ref017],[@ppat.1008239.ref019],[@ppat.1008239.ref029]\]. Different to WT mice, *Cgas*^*-/-*^ mice did not upregulate expression of the ISGs *Ifit3* ([Fig 2E](#ppat.1008239.g002){ref-type="fig"}), *Irf7* ([Fig 2F](#ppat.1008239.g002){ref-type="fig"}) *Isg15* ([Fig 2G](#ppat.1008239.g002){ref-type="fig"}), and *Mx1* ([Fig 2H](#ppat.1008239.g002){ref-type="fig"}) suggesting that the induction of ISGs by IFN-I and IFN-γ may be non-overlapping *in vivo*. To ensure that the significant decrease in IFN-I and ISG expression is inherently due to cGAS deficiency and not a challenge-specific phenomenon, we inoculated B6 and *Cgas*^*-/*^ mice with either ECTV or TLR9 agonist CpG and found that CpG inoculation in the footpad does not induce IFN-I or ISG expression at 2 d post challenge (*Il12* expression was used as a positive control and was found to be upregulated in both B6 and *Cgas*^*-/-*^ mice) ([S1 Fig](#ppat.1008239.s001){ref-type="supplementary-material"}). cGAS deficiency did not affect the transcription of the chemokine genes *Ccl2* ([Fig 2I](#ppat.1008239.g002){ref-type="fig"}) and *Ccl7* ([Fig 2J](#ppat.1008239.g002){ref-type="fig"}) that are important for iMO recruitment \[[@ppat.1008239.ref016]\], or *Cxcl9* ([Fig 2K](#ppat.1008239.g002){ref-type="fig"}), which is important for NK cell recruitment and dependent on IFN-γ during ECTV infection \[[@ppat.1008239.ref017]\]. Also, cGAS deficiency did not affect the transcription of the pro-inflammatory cytokine genes *Il12* ([Fig 2L](#ppat.1008239.g002){ref-type="fig"}), *Il6* ([Fig 2M](#ppat.1008239.g002){ref-type="fig"}) and *Tnf* ([Fig 2N](#ppat.1008239.g002){ref-type="fig"}). Together, these data suggest that the accelerated viral dissemination and increased susceptibility of *Cgas*^*-/-*^ mice to mousepox is likely due to significantly reduced global IFN-I production in the dLN and consequently, a dampened ISG response.

![*Cgas*^*-/-*^ mice have a defective IFN-I and ISG response in the dLN after infection.\
**(A-N)** Expression of IFN-Is (A-C), IFN-γ (D), ISGs (E-H) and proinflammatory chemokines/cytokines (I-N) in the dLN at 2.5 dpi of the indicated mice as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three similar experiments. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](ppat.1008239.g002){#ppat.1008239.g002}

cGAS expression in hematopoietic-derived cells is required for optimal IFN-I and ISG expression in the dLN {#sec014}
----------------------------------------------------------------------------------------------------------

Next, we made bone marrow chimeras to investigate whether cGAS expression in the hematopoietic compartment is required for an optimal IFN-I response and resistance to ECTV. The degree of donor BM reconstitution in the irradiated hosts was successful as there were approximately equivalent cellularity and total numbers of different immune cell subsets in the naïve contralateral LNs in all of the different groups ([S2 Fig](#ppat.1008239.s002){ref-type="supplementary-material"}). We found that *Cgas*^*-/-*^→*Cgas*^*-/-*^ and *Cgas*^*-/-*^→B6 chimeras succumbed to mousepox, while B6→ *Cgas*^*-/-*^ and B6→B6 chimeras survived ([Fig 3A](#ppat.1008239.g003){ref-type="fig"}). In agreement, compared to B6→B6 and B6→*Cgas*^*-/-*^ mice, *Cgas*^*-/-*^→*Cgas*^*-/-*^ and *Cgas*^*-/-*^→B6 mice had significantly higher virus transcripts in the dLN at 2.5 dpi ([Fig 3B](#ppat.1008239.g003){ref-type="fig"}) and higher infectious virus in the spleen ([Fig 3C](#ppat.1008239.g003){ref-type="fig"}) and liver ([Fig 3D](#ppat.1008239.g003){ref-type="fig"}) at 7 dpi. This indicates that ECTV control and resistance to mousepox requires cGAS expression in the hematopoietic compartment and not in the parenchyma. Accordingly, *Cgas*^*-/-*^→*Cgas*^*-/-*^ and *Cgas*^*-/-*^→B6 chimeras had significantly lower IFN-I expression in the dLN ([Fig 3E--3G](#ppat.1008239.g003){ref-type="fig"}) but not *Ifng* ([Fig 3H](#ppat.1008239.g003){ref-type="fig"}), *Cxcl9* ([Fig 3I](#ppat.1008239.g003){ref-type="fig"}), *Il6* ([Fig 3J](#ppat.1008239.g003){ref-type="fig"}), *Il12* ([Fig 3K](#ppat.1008239.g003){ref-type="fig"}) or *Tnf* ([Fig 3L](#ppat.1008239.g003){ref-type="fig"}). Finally, cGAS expression in the hematopoietic compartment was required for the expression of ISGs as *Cgas*^-/-^→*Cgas*^*-/-*^ and *Cgas*^*-/-*^→B6 chimeras had significantly reduced levels of ISGs in the dLN at 2.5 dpi ([Fig 3M--3P](#ppat.1008239.g003){ref-type="fig"}).

![cGAS expression in hematopoietic-derived cells is required for optimal IFN-I and ISG expression in the dLN.\
**(A)** Survival of the indicated mice **(B)** Expression of *Evm003* in the dLN of the indicated mice at 2 dpi as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of two similar experiments. **(C-D)** Virus loads in the spleen (C) and liver (D) of the indicated mice at 7 dpi as determined by plaque assay. Data are displayed as the mean ± SEM of 5 mice per group. **(E-P)** As in (B) measuring *Ifna4* (E), *Ifna-non4* (F), *Ifnb1* (G), *Ifng* (H), *Cxcl9* (I), *Il6* (J), *Il12* (K) *Tnf* (L), *Ifit3* (M), *Irf7* (N) *Isg15* (O) and *Mx1* (P). Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of two similar experiments. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](ppat.1008239.g003){#ppat.1008239.g003}

*Cgas*^*-/-*^ mice have an intrinsic defect in IFN-I expression and accumulation of MHC-II^hi^ DCs, iMOs and NK cells {#sec015}
---------------------------------------------------------------------------------------------------------------------

We have shown that both MHC-II^hi^ DCs and iMOs are important sources of IFN-I in the dLN after ECTV infection; MHC-II^hi^ DCs provide the early source of IFN-I in the dLN (\[[@ppat.1008239.ref060]\]) and are the principal cells that recruit iMOs, before infected iMOs take over as the major source of IFN-I in the dLN at later time points \[[@ppat.1008239.ref016]\]. To determine if the increased viral dissemination in *Cgas*^*-/-*^ mice was due to altered recruitment or functionality of MHC-II^hi^ DCs, we infected B6 and *Cgas*^*-/-*^ mice and analyzed the kinetics of MHC-II^hi^ DC recruitment to the dLN and found that the frequency of MHC-II^hi^ DCs did not change at 1--3 dpi ([Fig 4A and 4B](#ppat.1008239.g004){ref-type="fig"}) however, there was a significant reduction in total numbers of MHC-II^hi^ DCs in the dLN at both 2 and 3 dpi in *Cgas*^*-/-*^ mice ([Fig 4C](#ppat.1008239.g004){ref-type="fig"}). We further confirmed that cGAS deficiency did not inherently alter the ability of MHC-II^hi^ DCs to migrate to the dLN through the generation of 50:50 mixed B6+*Cgas*^*-/-*^ → B6 bone marrow chimeras and found equivalent frequencies and ratios of MHC-II^hi^ DCs in the dLN at 2 dpi ([Fig 4D and 4E](#ppat.1008239.g004){ref-type="fig"}). *Cgas*^*-/-*^ MHC-II^hi^ DCs appeared functionally intact, at least with respect to expression of intracellular CXCL9 ([S3A Fig](#ppat.1008239.s003){ref-type="supplementary-material"}), and surface expression of IFNAR1 ([S3B Fig](#ppat.1008239.s003){ref-type="supplementary-material"}), costimulatory molecules CD40, CD80 and CD86 ([S3C--S3E Fig](#ppat.1008239.s003){ref-type="supplementary-material"}), and the NKG2D ligands Rae1 and MULT1 which are necessary to active NK cells in the dLN \[[@ppat.1008239.ref017],[@ppat.1008239.ref019]\] ([S3F and S3G Fig](#ppat.1008239.s003){ref-type="supplementary-material"}). However, at 2.5 dpi with ECTV-dsRED, a significantly higher proportion of MHC-II^hi^ DCs were dsRED^+^ in the dLN of *Cgas*^*-/-*^ mice compared to B6 indicating that *Cgas*^*-/-*^ MHC-II^hi^ DCs are more susceptible to infection ([Fig 4F](#ppat.1008239.g004){ref-type="fig"}). When we sorted dsRED^+^ infected and dsRED^-^ uninfected MHC-II^hi^ DCs from B6 and *Cgas*^*-/-*^ mice, we found that *Cgas*^*-/-*^ MHC-II^hi^ DCs had significantly higher levels of viral gene mRNA at 2 dpi, suggesting that cGAS also has a cell-intrinsic role in anti-viral protection ([Fig 4G](#ppat.1008239.g004){ref-type="fig"}). Moreover, ECTV-dsRED^-^ MHC-II^hi^ DCs from *Cgas*^*-/-*^ mice had relatively high levels of viral transcription, likely indicating early infection, before dsRED becomes fluorescent ([Fig 4G](#ppat.1008239.g004){ref-type="fig"}). *Cgas*^*-/-*^ MHC-II^hi^ DCs did not upregulate *Ifna4* ([Fig 4H](#ppat.1008239.g004){ref-type="fig"}), *Ifna-non4* ([S3H Fig](#ppat.1008239.s003){ref-type="supplementary-material"}) and *Ifnb1* ([S3I Fig](#ppat.1008239.s003){ref-type="supplementary-material"}) and the ISGs *Ifit3* ([Fig 4I](#ppat.1008239.g004){ref-type="fig"}), *Irf7* ([S3J Fig](#ppat.1008239.s003){ref-type="supplementary-material"}), *Isg15* ([S3K Fig](#ppat.1008239.s003){ref-type="supplementary-material"}) and *Mx1* ([S3L Fig](#ppat.1008239.s003){ref-type="supplementary-material"}).

![*Cgas*^*-/-*^ mice have an intrinsic defect in IFN-I expression and accumulation of MHC-II^hi^ DCs, iMOs and NK cells.\
**(A)** Representative flow cytometry plots of MHC-II^hi^ DC frequency in the dLN at 2 dpi. **(B-C)** Calculated frequency (B) and total numbers (C) of MHC-II^hi^ DCs in the dLNs of the indicated mice at the indicated dpi. Data are displayed as the mean ± SEM of 12--15 mice per group combined from three independent experiments. **(D)** Representative flow cytometry plots of CD45.1 expression on MHC-II^hi^ DCs from bone marrow chimeras reconstituted with a 50:50 mix of B6 and *Cgas*^*-/-*^ bone marrow cells. **(E)** Calculated ratio of CD45.1/*Cgas*^*-/-*^ MHC-II^hi^ DCs from the ndLNs and dLNs of 50:50 mixed bone marrow chimeras at 2 dpi. **(F)** Frequency of ECTV-dsRED^+^MHC-II^hi^ DCs in the dLN of the indicated mice at 2 dpi. **(G-I)** Expression of mRNA for the indicated genes: *Evm003* (G), *Ifna4* (H) and *Ifit3* (I) from sorted uninfected and infected MHC-II^hi^ DCs from the dLN of the indicated mice at 2 dpi. Data are displayed as mean ± SEM of pooled cells from 6--8 mice per group in one experiment, which is representative of two similar experiments. P values were calculated based on three technical replicates. **(J)** Representative flow cytometry plots of CD11b^+^Gr-1^int^ iMO in the dLN of the indicated mice at 2.5 dpi. **(K-L)** As in (B-C) but for iMO. **(M-N)** As in D-E but for iMO. **(O)** Frequency of ECTV-dsRED^+^ iMO in the dLN of the indicated mice at 2.5 dpi. **(P-Q)** As in G-K but for sorted infected and uninfected iMO from the indicated mice at 2 dpi. **(R)** Representative flow cytometry plots of NK1.1^+^CD3^-^ NK cells. (S-T) As in D-E but for NK cells. **(U)** Frequency of ECTV-dsRED^+^ NK cells in the dLN of the indicated mice at 2.5 dpi. **(T)** Calculated frequency of Zombie^+^ cells in the dLN at 3 dpi from the indicated mice. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](ppat.1008239.g004){#ppat.1008239.g004}

Next, we analyzed whether cGAS deficiency altered iMO accumulation in the dLN. The frequencies of iMO in *Cgas*^*-/-*^ and B6 mice were similar at 1--3 dpi ([Fig 4J--4K](#ppat.1008239.g004){ref-type="fig"}). However, *Cgas*^*-/-*^ mice had a significant reduction in the total number of iMO in the dLN at 2 and 3 dpi ([Fig 4L](#ppat.1008239.g004){ref-type="fig"}). Yet, *Cgas*^*-/-*^ iMOs did not have an intrinsic defect in recruitment to the dLN as determined in 50:50 mixed B6-*Cgas*^*-/-*^ bone marrow chimeras ([Fig 4M and 4N](#ppat.1008239.g004){ref-type="fig"}). *Cgas*^*-/-*^ iMOs were more susceptible to infection ([Fig 4O](#ppat.1008239.g004){ref-type="fig"}) and did not upregulate IFN-I (*Ifna4* ([Fig 4P](#ppat.1008239.g004){ref-type="fig"}), *Ifna-non4* ([S3M Fig](#ppat.1008239.s003){ref-type="supplementary-material"}) and *Ifnb1* ([Fig 1N](#ppat.1008239.g001){ref-type="fig"}) or the ISGs (*Ifit3* ([Fig 4Q](#ppat.1008239.g004){ref-type="fig"}), *Irf7* ([S3O Fig](#ppat.1008239.s003){ref-type="supplementary-material"}), *Isg15* ([S3P Fig](#ppat.1008239.s003){ref-type="supplementary-material"}) and *Mx1* ([S3Q Fig](#ppat.1008239.s003){ref-type="supplementary-material"}) but did not differ from B6 iMOs in the frequencies that were CXCL9^+^ or TNF-α^+^ ([S3R and S3S Fig](#ppat.1008239.s003){ref-type="supplementary-material"}).

Optimal resistance to ECTV requires a robust NK cell response \[[@ppat.1008239.ref019],[@ppat.1008239.ref029]\]. Our previous work demonstrated that MHC-II^hi^ DCs and iMOs play a critical role in the induction and recruitment of circulating NK cells to the dLN \[[@ppat.1008239.ref017]\]. Therefore, we next determined whether *Cgas*^*-/-*^ mice have an altered NK cell response. As with MHC-II^hi^ DCs and iMOs, *Cgas*^*-/-*^ mice had similar frequencies of NK cells in the dLN at 1--3 dpi ([Fig 4R and 4S](#ppat.1008239.g004){ref-type="fig"}), but significant reduction in total numbers of NK cells at 2 and 3 dpi ([Fig 4T](#ppat.1008239.g004){ref-type="fig"}). *Cgas*^*-/-*^ NK cells were significantly more permissive to infection ([Fig 4U](#ppat.1008239.g004){ref-type="fig"}), however they were functionally intact, as *Cgas*^*-/-*^ mice had no significant differences in frequency of Granzyme B^+^, IFN-γ^+^ and TNF-α^+^ NK cells in the dLN compared to B6 controls ([S3T--S3V Fig](#ppat.1008239.s003){ref-type="supplementary-material"}).

We hypothesized that the decreased IFN-I expression and increased infection rate of MHC-II^hi^ DCs and iMOs in the dLN of *Cgas*^*-/-*^ mice could increase viral-induced cell death without affecting frequencies of MHC-II^hi^ DCs and iMOs. In agreement, at 3 dpi, there was a significant higher frequency of Zombie^+^ (dead) cells in the dLNs of *Cgas*^*-/-*^ than of B6 mice ([Fig 4V](#ppat.1008239.g004){ref-type="fig"}).

Administration of cGAMP to *Cgas*^*-/-*^ mice restores IFN-I expression and resistance to ECTV infection {#sec016}
--------------------------------------------------------------------------------------------------------

Binding of DNA to cGAS catalyzes the production of cGAMP which functions as a second messenger that activates STING \[[@ppat.1008239.ref030],[@ppat.1008239.ref031]\]. Therefore, we tested whether exogenous administration of cGAMP restores resistance to mousepox to *Cgas*^*-/-*^ mice. All *Cgas*^*-/-*^ mice that received cGAMP in the footpad prior to infection (cGAMP+ECTV) survived ([Fig 5A](#ppat.1008239.g005){ref-type="fig"}) with a concomitant significant reduction in viral replication in the dLN at 2 dpi ([Fig 5B](#ppat.1008239.g005){ref-type="fig"}). To determine whether the decrease in viral replication was due to cGAMP-mediated IFN-I induction in the dLN, we measured IFN-I transcripts in the dLN at 2 dpi, however, there was a drastic reduction in *Ifna4* ([Fig 5C](#ppat.1008239.g005){ref-type="fig"}) *Ifna-non4* ([Fig 5D](#ppat.1008239.g005){ref-type="fig"}) and *Ifnb1* ([Fig 5E](#ppat.1008239.g005){ref-type="fig"}).). Although cGAMP administration increased the recruitment of MHC-II^hi^ DCs to the dLN of both B6 and *Cgas*^*-/-*^ mice ([Fig 5F](#ppat.1008239.g005){ref-type="fig"}), there was a significant decrease in iMOs ([Fig 5G](#ppat.1008239.g005){ref-type="fig"}), which accounted for the decrease in IFN-I. These results suggested that cGAMP decreases viral replication in the skin of the footpad and curbs (but does not prevent) spread to the dLN. In agreement, at 2 dpi, there was significantly lower viral replication in the skin of the footpad in cGAMP+ECTV mice ([Fig 5H](#ppat.1008239.g005){ref-type="fig"}). Moreover, cGAMP+ECTV induced a strong increase in *Ifna4*, *Ifna-non4*, and *Ifnb1* expression in the skin of the footpad of B6 and *Cgas*^*-/-*^ mice ([Fig 5I--5K](#ppat.1008239.g005){ref-type="fig"}). Furthermore, cGAMP+ ECTV restored the expression of the ISGs *Ifit3*, *Irf7*, *Isg15* and *Mx1* in the skin ([Fig 5L and 5M](#ppat.1008239.g005){ref-type="fig"}), therefore, potentially contributing to diminishing viral replication in the skin with subsequent decrease in dissemination to the dLN.

![Administration of cyclic GMP-AMP (cGAMP) to *Cgas*^*-/-*^ mice restores IFN-I expression and resistance to ECTV infection.\
**(A)** Survival of the indicated mice. **(B-E)** Expression of *Evm003* (B), *Ifna4* (C), *Ifna-non4* (D) and *Ifnb1* (E) in the dLN of the indicated mice at 2 dpi as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three independent experiments. **(F-G)** Calculated total numbers of MHC-II^hi^ DCs (E) and iMO (F) in the dLN of the indicated mice at 2 dpi. Data are displayed as mean ± SEM with 12--15 mice per group combined from three similar, independent experiments. **(H-O)** Expression of *Evm003* (H), *Ifna4* (I), *Ifna-non4* (J), *Ifnb1* (K), Ifit3 (L), Irf7 (M), *Isg15* (N) and *Mx1* (O) in the skin of the indicated mice at 2 dpi as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three similar, independent experiments. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](ppat.1008239.g005){#ppat.1008239.g005}

cGAMP-mediated resistance to ECTV is mostly dependent on IRF7 {#sec017}
-------------------------------------------------------------

It is well-established that pathogen-recognition by cGAS catalyzes the formation of cGAMP which activates STING \[[@ppat.1008239.ref028],[@ppat.1008239.ref032]\]. While STING has been demonstrated to activate not only IRF3 but also IRF7 \[[@ppat.1008239.ref033],[@ppat.1008239.ref034]\], IRF3 has been overwhelmingly utilized to describe the canonical pathway of cGAS-STING signaling. However, we have previously demonstrated that IRF7, but not IRF3, is required for T1-IFN expression in the dLN and resistance to ECTV \[[@ppat.1008239.ref016]\]. Therefore, we investigated whether IRF7 is required for the anti-ECTV effects of cGAMP. We found that cGAMP administration to *Irf7*^-/-^ mice did not decrease ECTV gene expression in the skin ([Fig 6A](#ppat.1008239.g006){ref-type="fig"}) or dLN at 2 dpi ([Fig 6B](#ppat.1008239.g006){ref-type="fig"}). Also, ECTV-infected *Irf7*^-/-^ mice receiving cGAMP and ECTV upregulated transcription of *Ifna4* ([Fig 6C and 6F](#ppat.1008239.g006){ref-type="fig"}) and *Ifnb1* ([Fig 6D and 6G](#ppat.1008239.g006){ref-type="fig"}) but not of *Ifna-non4* ([Fig 6E and 6H](#ppat.1008239.g006){ref-type="fig"}) in the skin and dLN. IRF7 deficiency did not alter expression levels of proinflammatory cytokines and chemokines in the skin and dLN after ECTV or cGAMP+ECTV ([S4A--S4H Fig](#ppat.1008239.s004){ref-type="supplementary-material"}) indicating that the main role of IRF7 during ECTV infection is in IFN-I but not in pro-inflammatory cytokine induction. Furthermore, despite the *Ifna4* and *Ifnb1* increase, cGAMP and cGAMP+ECTV did not upregulate ISGs in the skin ([Fig 6I--6L](#ppat.1008239.g006){ref-type="fig"}) of *Irf7*^-/-^ mice. Also, the seemingly increased survival of *Irf7*^*-/-*^ mice treated with cGAMP in survival as compared to untreated controls, did not reach statistical significance ([Fig 6M](#ppat.1008239.g006){ref-type="fig"}).

![cGAMP-mediated resistance to ECTV is mostly dependent on IRF7.\
**(A-B)** Expression of *Evm036* in the skin (A) and dLN (B) in the skin of B6 and *Irf7*^*-/-*^ mice at 2 dpi as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three independent experiments. (**C-L**) As in (A-B) but for IFN-I expression in the skin (C-E), dLN (F-H) and ISGs in the skin (I-L). **(M)** Survival of the indicated mice. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](ppat.1008239.g006){#ppat.1008239.g006}

cGAMP-mediated ISG induction is dependent on IFNAR1 {#sec018}
---------------------------------------------------

The induction of ISGs requires IFN-I binding and signaling through IFNAR1 to induce an anti-viral state \[[@ppat.1008239.ref006],[@ppat.1008239.ref007]\]. After ECTV infection, *Ifnar1*^*-/-*^ mice had significantly higher levels of ECTV gene transcription than B6 controls in the skin of the footpad and in the dLN at 2 dpi whether receiving cGAMP or not ([Fig 7A and 7B](#ppat.1008239.g007){ref-type="fig"}). Furthermore, while IFN-I expression in the skin ([Fig 7C--7E](#ppat.1008239.g007){ref-type="fig"}) and dLN ([Fig 7F--7H](#ppat.1008239.g007){ref-type="fig"}) was unaffected by the absence of IFNAR1, *Ifnar1*^*-/-*^ mice were unable to upregulate ISGs ([Fig 7I--7L](#ppat.1008239.g007){ref-type="fig"}). IFNAR1 deficiency also did not alter proinflammatory cytokine and chemokine expression in the skin ([S5A--S5D Fig](#ppat.1008239.s005){ref-type="supplementary-material"}) or dLN ([S5E--S5H Fig](#ppat.1008239.s005){ref-type="supplementary-material"}) uncoupling IFN-I and proinflammatory cytokine induction. Moreover, cGAMP did not rescue *Ifnar1*^*-/-*^ mice from lethal mousepox ([Fig 7M](#ppat.1008239.g007){ref-type="fig"}). These data indicate a critical role for IFN-I signaling in cGAMP-mediated resistance to ECTV.

![cGAMP-mediated protection against ECTV is dependent on IFNAR1.\
**(A-B)** Expression of *Evm003* in the skin (A) and dLN (B) of B6 and *Ifnar1*^*-/-*^ mice at 2 dpi as determined by RT-qPCR. (C-H) Expression of IFN-I in the skin (C-E) and dLN (F-H) of B6 and *Ifnar1*^*-/-*^ mice at 2 dpi as determined by RT-qPCR. (I-L) Expression of ISGs in the skin of B6 and *Ifnar1*^*-/-*^ mice at 2 dpi as determined by RT-qPCR. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of two independent experiments. (M) Survival of the indicated mice. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](ppat.1008239.g007){#ppat.1008239.g007}

Discussion {#sec019}
==========

Our lab and others have been redefining the paradigm of the LN as not only an important site for lymphocyte priming but as an essential checkpoint to curb viral dissemination. Resistance to mousepox requires a multitude of components of the innate immune system, including a strong NK cell and IFN-I response \[[@ppat.1008239.ref016],[@ppat.1008239.ref019],[@ppat.1008239.ref029]\]. The early accumulation of NK cells in the dLN is required for restriction of ECTV lympho-hematogenous spread and protection from lethal mousepox \[[@ppat.1008239.ref019],[@ppat.1008239.ref029]\]. Moreover, we have recently dissected the pathway in which migratory DCs, group1 innate lymphoid cells (ILCs, mostly NK cells) and iMO collaborate to recruit circulating NK cells to the dLN \[[@ppat.1008239.ref017]\]. IFN-I exert a wide variety of pleotropic biological effects through the upregulation of ISGs, all of which collectively work to resist and control infection \[[@ppat.1008239.ref006]\]. The importance of IFN-I in acute viral infections is clearly demonstrated through IFNAR1 deficiency or blocking experiments, which predominantly increases viral replication, dissemination and lethality even for many non-species-specific viruses such as Zika virus, West Nile virus or Dengue Virus in mice \[[@ppat.1008239.ref008]--[@ppat.1008239.ref010],[@ppat.1008239.ref035]--[@ppat.1008239.ref038]\]. After ECTV infection, MHC-II^hi^ DCs migrate to the dLN and are responsible for the very early expression of IFN-I and the chemokines CCL2 and CCL7 that recruit iMO \[[@ppat.1008239.ref016]\]. Notably, TLR9 and MyD88 are indirectly necessary to bring iMO to the dLN and for resistance to mousepox. However, they are not directly necessary for IFN-I production \[[@ppat.1008239.ref016]\]. Instead, once infected, the incoming iMO use STING signaling to IRF7 and NF-κB to induce the expression of IFN-α and IFN-β respectively, thereby becoming the main source of IFN-I in the dLN \[[@ppat.1008239.ref016]\]. However, the mechanisms of IFN-I dependent resistance and the identity of the PRR upstream of STING that mediate IFN-I induction against acute ECTV infection remained unclear.

Identifying the major cytosolic DNA PRR for IFN-I induction by ECTV is important because ECTV is the archetype for a large number of viruses relevant to animal and human health that utilize the lympho-hematogenous route of dissemination. STING is a critical adaptor protein downstream of over 10 different cytosolic DNA sensors \[[@ppat.1008239.ref039]\]. We recently discounted DAI as the major PRR for ECTV \[[@ppat.1008239.ref016]\]. Another main candidate as an ECTV PRR was IFI204, the murine ortholog for the human IFI16 and member of the AIM2-like receptor family, because it was among the few genes that mapped to Rmp-4 on chromosome 1 that confers resistance to ECTV \[[@ppat.1008239.ref022]\]. Furthermore, IFI204 has been shown to be important in interacting with ASC and procaspase-1 to form the inflammasome and subsequent IL-1β release \[[@ppat.1008239.ref024]\] as well as induction of IFN-β expression in herpesvirus \[[@ppat.1008239.ref024]\], *L*. *monocytogenes* \[[@ppat.1008239.ref040]\], *F*. *novicida* \[[@ppat.1008239.ref023]\], and *M*. *bovis* infection \[[@ppat.1008239.ref041]\]. Our results show, however, that IFI204 is not essential for resistance to mousepox because all *Ifi204*^*-/-*^ mice survived infection, had similar viral titers in the liver as B6 mice, and their IFN-I expression in the dLN was the same as in B6 mice. Yet, while it appears that IFI204 is not the major PRR for IFN-I induction during ECTV infection, it may still play secondary role, or may have some role in inflammasome activation or a cell-death pathway that contribute to ECTV control. In support, *Ifi204*^*-/-*^ had slightly higher virus titers in the spleen than B6 mice.

The cGAS-STING pathway mediates IFN-I production *in vitro* in mouse cDCs \[[@ppat.1008239.ref042]\], macrophages and fibroblasts \[[@ppat.1008239.ref028]\], and in human embryonic kidney 293 cells \[[@ppat.1008239.ref043]\] after infection with the OPVs VACV or MVA. Moreover, cGAS-STING-dependent IFN-I production has been implicated in numerous infection models including herpes simplex virus \[[@ppat.1008239.ref028],[@ppat.1008239.ref044]\], adenovirus \[[@ppat.1008239.ref045]\], cytomegalovirus \[[@ppat.1008239.ref046]\], Kaposi's sarcoma-associated herpesvirus \[[@ppat.1008239.ref047]\] as well as retroviruses including HIV-1 and HIV-2 \[[@ppat.1008239.ref048]\]. Yet, the role of cGAS in protection against viruses that disseminate through the natural route of infection in natural hosts had not been studied. Very recently, Cheng and colleagues demonstrated that cGAS-STING-IRF3 is required for optimal induction of IFN-β in various cell types \[[@ppat.1008239.ref018]\]. Furthermore, Cheng et al. showed that cGAS is necessary for increased survival to mousepox at 10^6^ pfu but not to 3,000 pfu ECTV \[[@ppat.1008239.ref018]\]. Our present study partially confirms some of Cheng et al. results and significantly extends them. Different to Cheng et al., we found that *Cgas*^*-/-*^ mice were highly susceptible to lethal mousepox after infection with only 3,000 pfu ECTV. The reason for the difference between labs is unclear but may be due to differences in animal facilities such as, for example, changes in the microbiome.

Analysis of various transcripts in the dLN revealed that *Cgas*^*-/-*^ deficiency resulted in drastically reduced expression of IFN-I and downstream ISGs, which is the likely reason why viral replication and spread was increased, Yet, IFN-I and ISG induction was not completely ablated in the dLN of *Cgas*^-/-^ mice. This could be attributed to two reasons: **1)** While cGAS deficiency essentially completely ablates IFN-I expression in iMO and MHC-II^hi^ DCs, there could be other immune cell types that produce IFN-I independently of cGAS. **2)** Other cytosolic DNA sensors may recognize ECTV and induce some IFN-I. While DAI \[[@ppat.1008239.ref016]\] or IFI204 are not required for resistance against ECTV, they may still partially contribute to the IFN-I response. Notably, cGAS deficiency did not affect the transcription of proinflammatory cytokines/chemokines in the dLN indicating that their induction is fully dependent on other sensing pathways, such as TLR9, and that cGAS is likely dedicated to the induction of IFN-I and ISGs. Thus, the need for cGAS reinforces the importance of IFN-I in resistance to mousepox and the notion that cGAS can play a pivotal role in ISG induction after viral infection \[[@ppat.1008239.ref049]\].

The role of cGAS in the hematopoietic vs non-hematopoietic compartment in anti-viral control is unclear. Li et al. demonstrated that *Cgas*^*-/-*^ mouse fibroblasts failed to produce IFN-I \[[@ppat.1008239.ref028]\]. Furthermore, cGAS plays a role in human keratinocytes sensing of HSV-1 and VACV \[[@ppat.1008239.ref025]\] and the anti-tumor response in stromal cells \[[@ppat.1008239.ref050]\]. However, we have shown that during ECTV infection, IFN-I is mainly produced by BMD MHC-II^hi^ DCs and iMO, suggesting that the critical cells expressing cGAS should be BMD. Using bone marrow chimeras, we show that B6→B6 and B6→*Cgas*^*-/-*^ mice survived mousepox with significantly lower viral gene expression in the dLN and infectious virus in the liver than B6→*Cgas*^-/-^ and *Cgas*^-/-^→*Cgas*^-/-^, which succumbed to mousepox. This demonstrates that cGAS in hematopoietic cells but not in other tissues is essential for resistance to mousepox and virus control. Interestingly, B6 → *cGas*^*-/-*^ had significantly more virus in the liver than B6→B6 mice and *Cgas*^*-/-*^ →*Cgas*^-/-^ had more virus in the liver than *Cgas*^*-/-*^→B6 mice, suggesting a minor contribution in virus control by the parenchymal cells such as hepatocytes, or by radio-resistant, self-sustaining, innate immune cells derived from the yolk sac, such as Langerhans and/or Kupffer cells \[[@ppat.1008239.ref051],[@ppat.1008239.ref052]\]. In support, we have found that Langerhans cells are the main subset of MHC-II^hi^ DCs that are responsible for the accumulation of iMO in the dLN \[[@ppat.1008239.ref060]\]. Consistent with the survival data and the results with plain *Cgas*^-/-^ mice, however, IFN-I and ISG induction was significantly higher in B6→B6 and B6→*Cgas*^-/-^ compared to *Cgas*^-/-^→B6 and *Cgas*^-/-^→*Cgas*^-/-^ mice, suggesting that cells generated in the bone marrow are the main IFN-I producers and required for ISG expression.

Binding of DNA activates cGAS by inducing a conformational change in the cGAS active site. Activated cGAS catalyzes the synthesis of cyclic GMP-AMP (cGAMP), which functions as a second messenger for IFN-I induction by activating STING \[[@ppat.1008239.ref012],[@ppat.1008239.ref028],[@ppat.1008239.ref031]\]. cGAMP has been used as an adjuvant to boost antigen-specific T cell responses \[[@ppat.1008239.ref028]\] and in cutaneous vaccination against influenza \[[@ppat.1008239.ref053]\], mucosal vaccination \[[@ppat.1008239.ref054]\], and in various tumor models \[[@ppat.1008239.ref032],[@ppat.1008239.ref055],[@ppat.1008239.ref056]\]. We found that local administration of exogenous cGAMP in the footpad bypassed cGAS deficiency and fully rescued *Cgas*^*-/-*^ mice from lethal mousepox. Mechanistically, cGAMP primed the skin microenvironment to induce IFN-I and ISG transcription after ECTV infection, which reduced the level of local viral replication and, consequently, decreased viral dissemination to the dLN. Thus, the innate responses in the dLN were drastically decreased. Notably, despite that some viral dissemination still occurred, the mice were protected from lethal mousepox. These data indicates that early virus sensing by BMD cells and the subsequent IFN-I response at the initial site of entry may serve as a critical checkpoint to decrease lympho-hematogenous viral dissemination and resist systemic lethal disease. Notably, ECTV infection alone induced less IFN-I mRNA in the skin than ECTV+cGAMP. This could be due to the many immune evasion molecules encoded by ECTV and other poxviruses \[[@ppat.1008239.ref057]\]. For example, VACV inhibits the activation of STING, and Cowpox and ECTV inhibit STING dimerization *in vitro* \[[@ppat.1008239.ref058]\]. Also of interest, cGAMP alone also induced little IFN-I suggesting that in addition to cGAMP production by cGAS, other virus-sensing mechanisms are required for IFN-I expression. Surprisingly, cGAMP administration induced a stronger IFN-I response in the skin of *Cgas*^*-/-*^ than in B6 mice. Our experiments provide a snapshot of the differential IFN-I response in the skin of B6 and *Cgas*^-/-^ at 2 dpi. While the importance of these differences remain unknown, our data suggest that cGAS may provide a negative feedback signal in the skin, which contains a complex microbiome. Future experiments will focus on the administration of cGAMP at different time points pre- and post-infection, as well as different routes of administration, to assess how cGAMP modulates the innate and adaptive responses and evaluate cGAMP's efficacy as an effective adjuvant in anti-viral therapeutics.

Following cGAMP binding, the endoplasmic-reticulum (ER)-membrane adaptor STING \[[@ppat.1008239.ref012]\] becomes activated and traffics to the ER-Golgi intermediate compartment and the Golgi apparatus, to activate TANK binding kinase 1 (TBK1). It is commonly described that activated TBK1 phosphorylates IRF3 or IKK which then phosphorylates NF-kB \[[@ppat.1008239.ref012]\]. Activated IRF3, NF-kB and other transcription factors traffic to the nucleus to bind to the promoters and induce the expression of IFN-I and proinflammatory cytokines including IL-6, TNF, and IL-1β \[[@ppat.1008239.ref012]\]. While STING was originally shown to activate not only IRF3 but also IRF7 \[[@ppat.1008239.ref033]\] and IRF3 and IRF7 have been shown to have non-redundant roles in different infection models \[[@ppat.1008239.ref059]\], IRF3 is generally described in reviews as the main IRF downstream of cGAS and STING \[[@ppat.1008239.ref028]\]. Cheng et al. showed that transcription of *Ifnb1* by murine L929 and RAW264.7 cells infected with ECTV required cGAS-STING-IRF3. Yet, they did not confirm their results in IRF3 or IRF7 deficient mice *in vivo* \[[@ppat.1008239.ref018]\]. In previous work we showed that the expression of IFN-α in the dLN is dependent on IRF7 and not IRF3 and that IRF7 but not IRF3 is required for resistance to mousepox \[[@ppat.1008239.ref016]\]. In agreement, here we found that cGAMP did not promote significant survival of *Irf7*^*-/-*^ mice to mousepox, did not decrease viral replication in the skin, and did not promote *Ifna-non4* expression in the skin which emphasizes that cGAS-STING-IRF7 is the predominant IFN-I-inducing pathway in the skin and dLN during ECTV infection.

Finally, we showed that ECTV+ cGAMP failed to prevent viral replication and lethal mousepox in *Ifnar1*^*-/-*^ mice. Analysis of gene transcription showed that *Ifnar1*^*-/-*^ mice upregulated IFN-I and proinflammatory cytokine genes in both the skin and dLN to higher levels than B6 mice probably due to the increased virus loads. Yet, *Ifnar1*^*-/-*^ mice did not upregulate ISGs. These results indicate that the main mechanism of action of cGAMP is through the induction of ISGs by IFN-I.

In summary, here we demonstrate that cGAS-mediated IFN-I and ISG induction in the hematopoietic compartment is required for protection against ECTV. We also show that increased susceptibility due to cGAS deficiency can be overridden by local cGAMP administration. Mechanistically, cGAMP decreases viral replication in the skin and lympho-hematogenous viral dissemination by activating ISGs *via* a pathway that requires IRF7, IFN-I and IFNAR. Together, these results highlight the importance of cGAS as the major cytosolic DNA sensor to ECTV and provide important insights into the innate mechanism that can curb viral dissemination from the initial site of infection, and its importance for overall virus control.

Supporting information {#sec020}
======================

###### CpG does not induce IFN-I and ISG expression in the dLN of B6 or *Cgas*^*-/-*^ mice.

B6 or *Cgas*^*-/-*^ mice were either infected with 3,000 pfu ECTV or given 25 ug CpG in the footpad. LNs were harvested at 2 dpi. Data are displayed as mean ± SEM from 5 mice per group in experiment, which is representative of two similar experiments. For all, \*p\<0.05.

(TIF)

###### 

Click here for additional data file.

###### Efficiency of B6-*Cgas*^*-/-*^ BM chimera reconstitution.

(**A**) Total cellularity of the naïve contralateral LNs of B6-*Cgas*^*-/-*^ chimeric mice. (**B-G**) Total numbers of the indicated immune cell subtype in the naïve contralateral LNs of B6-*Cgas*^*-/-*^ chimeric mice. Data are displayed as mean ± SEM with 10--15 mice per group combined from three similar, independent experiments.

(TIF)

###### 

Click here for additional data file.

###### *Cgas*^*-/-*^ mice have an intrinsic defect in IFN-I expression and accumulation of MHC-II^hi^ DCs, iMOs and NK cells.

**(A)** Frequency of CXCL9^+^MHC-II^hi^ DCs in the dLN of the indicated mice at 2.5 dpi. **(B-G)** MFI of IFNAR1 (B), costimulatory molecules CD40 (C), CD80 (D) and CD86 (E), and NKG2D ligands Rae1 (G) and MULT1 (G). Data are displayed as mean ± SEM of 10--12 mice per group combined from three independent experiments. **(H-L)** Expression of mRNA for *Ifna-non4* (H), *Ifnb1* (I), *Irf7* (J), *Isg15* (K) and *Mx1* (L) from sorted uninfected and infected MHC-II^hi^ DCs from the dLN of the indicated mice at 2 dpi. Data are displayed as mean ± SEM of pooled cells from 6--8 mice per group in one experiment, which is representative of two similar experiments. P values were calculated based on three technical replicates. **(M-Q)** As in (H-L) but for iMO. (R-S) Frequency of CXCL9^+^ and TNF-α^+^ iMO in the dLN at 2.5 dpi during ECTV infection. (**T-V**) Frequencies of Granzyme B^+^ (T), IFN-γ^+^ (U), and TNF-α^+^ (V) NK cells in the dLN of the indicated mice at 2.5 dpi. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.

(TIF)

###### 

Click here for additional data file.

###### Proinflammatory cytokine and chemokine expression in *Irf7*^*-/-*^ mice.

(A-H) Expression of proinflammatory cytokines and chemokines in the skin (A-D) and dLN (E-H) of B6 and *Irf7*^*-/-*^ mice at 2 dpi with or without cGAMP administration. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three independent experiments. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.

(TIF)

###### 

Click here for additional data file.

###### Proinflammatory cytokine and chemokine expression in *Ifnar1*^*-/-*^ mice.

(A-H) Expression of proinflammatory cytokines and chemokines in the skin (A-D) and dLN (E-H) of B6 and *Ifnar*^*-/-*^ mice at 2 dpi with or without cGAMP administration. Data are displayed as mean ± SEM from 5 mice per group in one experiment, which is representative of three independent experiments. For all, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.

(TIF)

###### 

Click here for additional data file.
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11 Sep 2019

Dear Dr. Sigal,

Thank you very much for submitting your manuscript \"Resistance to an acute viral disease requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy\" (PPATHOGENS-D-19-01493) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time. All three reviewers thought your study was technically sound, although concern was raised about novelty because of the recent publication by Cheng et al. Two of the reviewers were more positive, but all three had questions, recommended experiments, and controls. I ask you to address all of the reviewers\' comments. In particular, the additional controls recommended by Reviewers 1 and 3 are necessary, as are experiments further characterizing lymphocytes in draining lymph nodes, viral burden in other organs, and assessment of cellularity in lymph nodes after cGAMP + ECTV. Additional experiments to determine whether cGAMP alters cellularity in the lymph nodes of IRF7- and IFNAR1-deficient mice also would be useful. If you choose not to do additional experimentation to address certain reviewer questions, please carefully justify your reasons in your rebuttal. Overall, this is a nice study that will be of interest to readers of PLOS Pathogens with some further experimentation and mechanistic detail. The reviews are appended below.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Additionally, to enhance the reproducibility of your results, PLOS recommends that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods>

We hope to receive your revised manuscript within 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.

We are sorry that we cannot be more positive about your manuscript at this stage, but if you have any concerns or questions, please do not hesitate to contact us.

Sincerely,

Jonathan Miner

Guest Editor

PLOS Pathogens

Michael Diamond

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Grant McFadden

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-2556-3526](http://orcid.org/0000-0002-2556-3526)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: The authors describe the importance of Cgas in resistance to mouse pathogen ectromelia virus (ECTV). Some of the novelty is taken out by the recent publication by Cheng et al. (as also mentioned by the authors). However, the aim of the study is still important enough for publication by PP as it seeks to deepen the understanding of what cells are central to the phenotype of increased susceptibility in Cgas deficient mice. This contribution is mostly focused in figure 3 and 4. These figures need to increase the number of relevant basic controls for those to be valid. Major and minor concerns are found below:

Reviewer \#2: This study by Wong et al described innate immune response to mouse ectromelia virus (ECTV), a poxvirus. The authors performed several sets of in vivo experiments with various mouse knockout strains lacking key components of the DNA sensing and interferon response pathways. They showed that innate immune response to and host protection against ECTV are dependent on cytosolic DNA sensor cGAS, not IFI204, and this is mediated via hematopoietic cells. They also showed that cGAMP treatment in mice confers protection against ECTV through IRF7 and IFNAR.

Reviewer \#3: In the manuscript entitled "Resistance to an acute viral disease requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy" Wong et al provide evidence suggesting that cGAS is the upstream sensor of Ectromelia Virus (ECTV) and is required in hematopoietic cells. cGAS deficiency impacts IFN-I expression and accumulation of MHC-IIhi DCs, iMOs and NK cells. cGAMP administration restores resistance to ECTV infection which is dependent on IRF7 and IFNAR1. Even though cGAS has been identified as a sensor during ECTV infection, the authors provide important evidence in terms of the cell types impacted by cGAS deficiency in controlling this virus. Data suggesting administration of cGAMP as a therapy during infections, is also an interesting and promising idea. However, some issues would need to be addressed.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: Figure 2: Is the difference in IFN-I and ISG dependent on the challenge? What if you challenged with TLR9 agonist CpG? Does the difference persist? This is an important control to test if it is truly an effect of CpG being engaged by the virus -- or -- a basal lack of IFN-I/ISGs due Cgas deficiency.

Figure 3 is the most important figure in distinguishing this work from the work of Cheng et al. However, some important controls and important analysis are missing:

Fig 3A: How successful was the chimera--generation? Have the authors tested if the adoptively transferred bone.marrow cells led to a functional haematopoetic compartment? Was there a difference in how well the Cgas KO bone-marrow established itself in the recipient compared with the wt bone-marrow? Do the transferred cells have equal amount of TLR9? / or respond equally well to CpG DNA? What about at the time of infection? Has something changed?

Figure 4

Fig 4C, L, and T: How can there be "no difference" in percentage of MHC-IIHI DCs but a clear difference in total number of cells? This must mean that other cell types must also have increased in numbers. How was the number of cells calculated? Was it per weight of the dLN? Or were the dLNs just different in size between mouse strains? May I missed it in the text, but I can´t find a description of this. This should be clarified. Also, the authors should use dots instead of bars to make clear the distribution of data points.

Reviewer \#2: I do not have any major concerns regarding the technical aspect of the experiments. Most experiments are very well designed, and the results are convincing (although expected).

However, the conceptual and mechanistic novelty of this study are very limited. Almost all of the conclusions are well expected from existing literature on poxvirus sensing by the cGAS-STING pathway, cGAMP is known to stimulates interferon and antiviral response through IRFs and IFNAR. The Cheng et al study (ref 18) last year used the exact same virus ECTV and has already demonstrated many of the similar observations. I appreciate the extensive efforts the authors put in with many of the in vivo mouse studies presented here, but they reveal very little novel mechanistic insights.

Reviewer \#3: Specific issues:

1\. In the 50:50 mixed B6-cGAS-/- bone marrow chimeras, the authors show that MHC-IIhi DCs, iMOs and NK cells were the main cell types impacted. Could they also comment on the distribution of other cells in the LN like T cells in these experiments.

2\. The authors comment that "cGAMP decreases viral replication in the skin " however cGAS expression in non-hematopoietic cells has little effect on viral load in the spleen and liver measured at 7dpi (Figure 3). The viral gene expression in the dLN in the same figure is measured at 2dpi. What happens to viral loads in the spleen and liver at 2dpi dose? Is it possible that the role of cGAS in non-hematopoietic cells is dose dependent ? What is the ISG expression in skin in these chimeric mice?

3\. The authors mention that the decreased IFN-I expression and increased infection rate of MHC-IIhi DCs and iMOs in the dLN of Cgas-/- mice could increase viral-induced cell death without affecting frequencies of MHC-IIhi DCs and iMOs. Do the authors have a way to quantify this ?

4\. Figure 5 points out that administration of cGAMP 4 hrs prior to ECTV infection restores viral resistance however the gene expression data and cellular numbers in LN are not convincing.

"However, there was a drastic reduction in Ifna4 (Figure 5C) Ifna-non4 (Figure 5D) and Ifnb1 (Figure 5E), as well as a significant reduction in total numbers of MHC-IIhi DCs (Figure 5F) and iMOs (Figure 5G)." Please indicate what is the comparison here. Have the authors looked into cell frequencies in LN after cGAMP + ECTV? What about viral load in spleen and liver in ECTV+cGAMP conditions? What cells are infiltrating the skin after cGAMP administration?

5\. cGAMP administration to IRF7 KOs does significantly change a set of genes in ECTV+cGAMP condition as compared to ECTV+cGAMP in B6 such as Ifna4 (skin Fig 6C) , Ifna-non4 in skin and dLN (Figure 6 E and H). A set of genes Ifit3, Isg15 and Mx1 were only tested in skin and not in LN. It's not clear from the data presented if all the effects are IRF7 dependent? Why do a set of genes change and others don't ? This is observed in other figures too, Figure 5J in B6 mice ECTV compared to ECTV+cGGAMP ifna4 is significantly upregulated but ifna-non4, Ifnb1 are unchanged. cGAMP administration in B6 mice would likely enhance all ISGs.

6\. What is the status of MHC-IIhi DCs and iMOs (numbers or frequencies) in dLN in IRF7 or IFNAR deficient mice treated with cGAMP?

7\. In Figure 7 C and D why ifna-4 and Ifna-non4 are increased in the skin but not in dLN of IFNAR1 deficient mice , comparing ECTV +cGAMP in B6 to ECTV+ cGAMP in IFNAR KO? Are there different cell types infiltrating these two tissues after cGAMP administration?

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: Headline: As the manuscript is only about one single type of virus -- then I think "an acute viral disease" should be replaced by the name of the actual disease/infection.

The two separated sections that both refer to figure 1 should be merged.

Fig 4G: Could the authors clarify what this panel measures. Is it uninfected mice that have such a high level of evm003 expression?

Figure 5:

This figure is not really informative besides the point that cGAMP can induce IFN-I, which we already know can protect from infection. Admin of other IFN-I inducing agents, or IFN-I itself, is likely to have same effect. Therefore, these experiments neither support nor stand against the hypothesis that Cgas is important for the resistance.

Figure 6:

From Figure 6M it is clear that the effect of cGAMP is only partly dependent on Irf7. This should be reflected in the figure caption.

Reviewer \#2: Some minor comments:

1\. cGAS knockout mice has reduced ISG expression at baseline. Some of the ISG measurements (e.g. Figure 2) need to show before and after infection values. The 2-fold decrease in most ISGs after infection may be similar to that of before infection, if so, that will complicate the interpretation of ISGs.

2\. Poxvirus antagonize cGAS pathway through poxins that cleaves cGAMP (PMID: 30728498). Does ECTV encode a poxin to antagonize cGAMP?

3\. The discussion is too long. Much of the content is comparing the Cheng et al study rather than highlighting the implication of some of the findings.

Reviewer \#3: Throughout the manuscript its difficult to follow which conditions are being compared to draw clear conclusions. Additional information in legend or text would help the reader. Please state what conditions are controls and what conditions are being tested.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

12 Nov 2019

Dear Dr. Sigal:

Thank you very much for submitting your manuscript \"Resistance to Ectromelia virus infection requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy\" (PPATHOGENS-D-19-01493R1) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

We therefore ask you to modify the manuscript according to the review recommendations (place data in a Supplemental Figure as described below) before we can consider your manuscript for acceptance. 

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

We hope to receive your revised manuscript within 60 days or less. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email.

\[LINK\]

If you have any questions or concerns while you make these revisions, please let us know.

Sincerely,

Jonathan Miner

Guest Editor

PLOS Pathogens

Michael Diamond

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Grant McFadden

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-2556-3526](http://orcid.org/0000-0002-2556-3526)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

The revised manuscript has adequately addressed all of the reviewer concerns. However, prior to acceptance of your revised manuscript for publication, we recommend that some key controls requested by the reviewers are included as supporting data. Specifically, data included in Reviewer Figure 1 and the bone marrow reconstitution efficiency should included in the supporting information, since these results are critical for interpretation of your findings.

10.1371/journal.ppat.1008239.r004
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25 Nov 2019

Dear Dr. Sigal,

We are pleased to inform that your manuscript, \"Resistance to Ectromelia virus infection requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy\", has been editorially accepted for publication at PLOS Pathogens. 

Before your manuscript can be formally accepted and sent to production, you will need to complete our formatting changes, which you will receive by email within a week. Please note that your manuscript will not be scheduled for publication until you have made the required changes.

IMPORTANT NOTES

\(1\) Please note, once your paper is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plospathogens@plos.org>.

\(2\) Copyediting and Proofreading: The corresponding author will receive a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. 

\(3\) Appropriate Figure Files: Please remove all name and figure \# text from your figure files. Please also take this time to check that your figures are of high resolution, which will improve the readbility of your figures and help expedite your manuscript\'s publication. Please note that figures must have been originally created at 300dpi or higher. Do not manually increase the resolution of your files. For instructions on how to properly obtain high quality images, please review our Figure Guidelines, with examples at: <http://journals.plos.org/plospathogens/s/figures>.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

\(4\) Striking Image: Please upload a striking still image to accompany your article if one is available (you can include a new image or an existing one from within your manuscript). Should your paper be accepted, this image will be considered for our monthly issue image and may also appear on our website to feature your article. Please upload this as a separate file, selecting \"striking image\" as the file type upon upload. Please also include a separate \"Other\" file with a caption, including credits and any potential copyright information. Please do not include the caption in the main article file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plospathogens/s/content-license>. Please note that PLOS cannot publish copyrighted images.

\(5\) Press Release or Related Media: If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team in advance at <plospathogens@plos.org> as soon as possible. We ask that you contact us within one week to plan ahead of our fast Production schedule. If you need to know your paper\'s publication date for related media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. 

(6)  PLOS requires an ORCID iD for all corresponding authors on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager.  To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager

\(7\) Update your Profile Information: Now that your manuscript has been provisionally accepted, please log into Editorial Manager and update your profile, if needed. Go to <https://www.editorialmanager.com/ppathogens>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process. 

\(8\) LaTeX users only: Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines <http://journals.plos.org/plospathogens/s/latex> in the meantime.

(9) If you have associated protocols in protocols.io, please ensure that you make them public before publication to guarantee immediate access to the methodological details.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens. 

Best regards,

Jonathan Miner

Guest Editor

PLOS Pathogens

Michael Diamond

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Grant McFadden

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-2556-3526](http://orcid.org/0000-0002-2556-3526)

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer Comments (if any, and for reference):

10.1371/journal.ppat.1008239.r005
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19 Dec 2019

Dear Dr. Sigal,

We are delighted to inform you that your manuscript, \"Resistance to Ectromelia virus infection requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Grant McFadden

Editor-in-Chief

PLOS Pathogens

[orcid.org/0000-0002-2556-3526](http://orcid.org/0000-0002-2556-3526)
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